Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins also elevate high-density lipoprotein cholesterol (HDL-C) in a dose-dependent manner by up to + 10% [32].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [32]
In the citing paper
“Moreover, the long-term safety of the regular consumption of these products has not been fully documented and safety issues due to the possible presence of contaminants in some preparations have been raised.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C levels to variable extents, but the consumer is not able to make that distinction [144,185].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“Hypocholesterolaemic effects of RYR are related to a statin-like mechanism-inhibition of hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase-of monacolins, which represent the bioactive ingredient.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [185]
In the citing paper
“In a meta-analysis 291 of several intervention studies in dyslipidaemic patients, elevations in HDL-C varied with dose among the respective statins; such elevations were typically in the range of 5-10%.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [291]
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Diabetes and atherosclerosis: An epidemiologic view
Pyörälä, K., Laakso, M., & Uusitupa, M. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 919
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Self-citationPedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., McGarry, T., Bettis, R., Melani, L., Lipka, L. J., LeBeaut, A. P., Suresh, R., Sun, S., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 558
de Grooth, G. J., Kuivenhoven, J. A., Stalenhoef, A. F. H., de Graaf, J., Zwinderman, A. H., Posma, J. L., van Tol, A., & Kastelein, J. J. P. (2002) · Circulation · doi:10.1161/01.cir.0000015857.31889.7b · Cited by 456
Comparison of statins in hypertriglyceridemia
Stein, E. A., Lane, M., & Laskarzewski, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00041-1 · Cited by 386
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Aviram, M., Rosenblat, M., Bisgaier, C. L., & Newton, R. S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00032-x · Cited by 296
Guerin, M., Lassel, T. S., Le Goff, W., Farnier, M., & Chapman, M. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.1.189 · Cited by 237
Davidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkena, R., Fayyad, R., & Black, D. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00174-4 · Cited by 233
Davidson, M., Ma, P., Stein, E. A., Gotto, A. M., Raza, A., Chitra, R., & Hutchinson, H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02226-3 · Cited by 230
Cheung, M. C., Zhao, X.-Q., Chait, A., Albers, J. J., & Brown, B. G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0801.095151 · Cited by 190
Bays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson-Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 179
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 177
Schuster, H., Barter, P. J., Stender, S., Cheung, R. C., Bonnet, J., Morrell, J. M., Watkins, C., Kallend, D., & Raza, A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.004 · Cited by 160
Self-citationJONES, P., Hunninghake, D. B., Ferdinand, K. C., Stein, E., Gold, A., Caplan, R. J., & Blasetto, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.006 · Cited by 124
Tamehiro, N., Shigemoto-Mogami, Y., Kakeya, T., Okuhira, K.-I., Suzuki, K., Sato, R., Nagao, T., & Nishimaki-Mogami, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701228200 · Cited by 101
Asztalos, B. F., Maulf, F. L., Dallal, G. E., Stein, E. A., Jones, P. H., Horvath, K. V., McTaggart, F., & Schaefer, E. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.117 · Cited by 84
Johansson, J., OLSSON, A. G., Bergstrand, L., Elinder, L. S., Nilsson, S., Erikson, U., Mölgaard, J., Holme, I., & Walldius, G. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.8.1049 · Cited by 82
Pedersen, T. R., OLSSON, A. G., F˦rgeman, O., KJEKSHUS, J. K., Wedel, H., Kjekshus, K. R., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyor, K., et al. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.030 · Cited by 72
Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients
Asztalos, B. F., Horvath, K. V., McNamara, J. R., Roheim, P. S., Rubinstein, J. J., & Schaefer, E. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200037-jlr200 · Cited by 65
Kassai, A., Illyés, L., Mirdamadi, H. Z., Seres, I., Kalmár, T., Audikovszky, M., & Paragh, G. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.05.016 · Cited by 54
Berk-Planken, I., Hoogerbrugge, N., Stolk, R., Bootsma, A., & Jansen, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.427 · Cited by 51
Homma, Y., Ozawa, H., Kobayashi, T., Yamaguchi, H., Sakane, H., & Nakamura, H. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05487-4 · Cited by 50
Després, J. ‐., Lemieux, I., Salomon, H., & Delaval, D. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00988.x · Cited by 44
Coronary atherosclerosis can regress with very intensive statin therapy.
Sipahi, I., Nicholls, S. J., Tuzcu, E. M., & Nissen, S. E. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.10.937 · Cited by 42
Self-citationFærgeman, O., Hill, L., Windler, E., Wiklund, O., Asmar, R., Duffield, E. L., & Sosef, F. (2008) · Cardiology · doi:10.1159/000127442 · Cited by 40
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study
Cheung, R. C., Morrell, J. M., Kallend, D. G., Watkins, C. L., & Schuster, H. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.12.011 · Cited by 26
Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans.
McPherson, R. (1999) · PubMed · Cited by 13
le Roux, C. W., Murphy, E., & Seed, M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80026-1 · Cited by 10
Mänttäri, M., Tenkanen, L., Mäenpää, H. O., Manninen, V., & Huttunen, J. K. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.171 · Cited by 6
Factors predictive of marked decrease in HDL-C by probucol treatment.
Yashiro, A., Nakashima, Y., Segawa, J., Kawashima, T., & Kuroiwa, A. (1990) · PubMed · Cited by 2
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., Borgman, M., Wolski, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110874 · Cited by 890
Self-citation
Metadata
- Authors
- Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J.
- Affiliations
- The Heart Research Institute (AU)
- Keele University (GB)
- Cleveland Clinic (US)
- Corresponding author
- Barter, Philip J.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 51
- Issue
- 6
- Pages
- 1546-1553
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC3035518
- OpenAlex
- W2134105637
- Cited by
- 259
- References
- 38
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 11 · 2021: 19 · 2020: 17 · 2019: 8 · 2018: 16 · 2017: 11 · 2016: 15 · 2015: 15 · 2014: 23 · 2013: 15 · 2012: 13
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3790 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, HDL cholesterol, LDL cholesterol, rosuvastatin, atorvastatin, simvastatin, apolipoprotein A-I, triglycerides, diabetes mellitus, dyslipidemia, statin dose
- MeSH terms
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.